Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis

Journal of Managed Care Pharmacy

Volumn 18, Issue 9 B, 2012, Pages

  Bandari, Daniel S ^a   Sternaman, Debora ^a   Chan, Theodore ^a   Prostko, Chris R ^a   Sapir, Tamar ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ALOPECIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BIRTH DEFECT; BLOOD BRAIN BARRIER; BRADYCARDIA; CARDIOTOXICITY; CAREGIVER; COMPETITIVE INHIBITION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMYELINATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; INJECTION SITE REACTION; LIFESTYLE; LIPOATROPHY; LOW DRUG DOSE; MANAGED CARE; MEDICAL DECISION MAKING; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RETINA MACULA EDEMA; RISK BENEFIT ANALYSIS; SIDE EFFECT; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH INSURANCE; MALE; PATHOPHYSIOLOGY; PHARMACOECONOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ECONOMICS, PHARMACEUTICAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MANAGED CARE PROGRAMS; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84872587971     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.s9-b.1     Document Type: Article

References (113)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-52.
2. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93(1):1-12.
3. Brück W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci. 2003;24(Suppl 5):S265-S267.
4. National Multiple Sclerosis Society. Who gets MS? 2012. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-knowabout-ms/who-gets-ms/index.aspx. Accessed November 18, 2012.
5. Myhr KM. Diagnosis and treatment of multiple sclerosis. Acta Neurol Scand Suppl. 2008;188:12-21.
6. Jobin C, Larochelle C, Parpal H, Coyle PK, Duquette P. Gender issues in multiple sclerosis: an update. Womens Health (Lond Engl). 2010;6(6):797-820.
7. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28(5):363-79.
8. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-702.
9. Wingerchuk DM. Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med. 2011;78(2):221-30.
10. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61(6):504-13.
11. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832-38.
12. Handel AE, Williamson AJ, Disanto G, et al. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One. 2011;6(1):e16149.
13. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol. 2006;59(3):499-503.
14. Compston A, Sawcer S. Genetic analysis of multiple sclerosis. Curr Neurol Neurosci Rep. 2002;2(3):259-66.
15. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003;72(3):710-16.
16. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol. 2012;142(1):2-8.
17. Bo L, Geurts JJ, Mork SJ, van der Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl. 2006;183:48-50.
18. National Multiple Sclerosis Society. What we know about MS: symptoms. Available at: http://www.nationalmssociety.org/about-multiple-sclerosis/whatwe-know-about-ms/symptoms/index.aspx. Accessed November 18, 2012.
19. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-11.
20. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.
21. Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther. 2003;98(2):245-55.
22. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999;67(2):148-52.
23. National Multiple Sclerosis Society. What is MS? Four disease courses have been identified in MS. 2012. Available at: http://www.nationalmssociety. org/about-multiple-sclerosis/what-we-know-about-ms/what-is-ms/fourdisease-courses-of-ms/index.aspx. Accessed November 18, 2012.
24. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-69.
25. Sperandeo K, Nogrady L, Moreo K, Prostko CR. Managed approaches to multiple sclerosis in special populations. J Manag Care Pharm. 2011;17(9 Suppl C):S1-S19.
26. Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin. 2009;25(4):869-77.
27. Lazzaro C, Bianchi C, Peracino L, Zacchetti P, Uccelli A. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci. 2009;30(1):21-31.
28. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52.
29. Burks J. MS: the treatment paradigm, a pathway to success for improved patient outcomes. J Manag Care Med. 2008;12(1):26-31.
30. Kobelt G. Health economic issues in MS. Int MS J. 2006;13(1):17-26.
31. Cheng EM, Crandall CJ, Bever CT Jr., et al. Quality indicators for multiple sclerosis. Mult Scler. 2010;16(8):970-80.
32. Singh V, Hintzen RQ, Luider TM, Stoop MP. Proteomics technologies for biomarker discovery in multiple sclerosis. J Neuroimmunol. 2012;248(1-2):40-47.
33. Ziemann U, Wahl M, Hattingen E, Tumani H. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol. 2011;95(4):670-85.
34. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci. 2011;305(1-2):1-10.
35. Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence. 2011;5:101-08.
36. U.S.Food and Drug Administration. FDA approves new multiple sclerosis treatment Aubagio. September 12, 2012. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm. Accessed November 18, 2012.
37. Perumal J, Khan O. Emerging disease-modifying therapies in multiple sclerosis. Curr Treat Options Neurol. 2012;14(3):256-63.
38. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158(5):1173-82.
39. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
40. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15.
41. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745-58.
42. O'Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007;7(1):123-36.
43. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
44. Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs. 2011;25(6):491-502.
45. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res. 2011;317(9):1301-11.
46. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007;4(4):647-53.
47. Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2012;12(4):371-84.
48. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
49. Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25(5):401-14.
50. Warnke C, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009;5:333-40.
51. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.
52. Gold R, Kappos L, Bar-Or A, et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial [abstract 95]. Mult Scler. 2011;17(Suppl):S9-S52.
53. Selmaj K, Gold R, Kappos L et al. Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2011;17(Suppl 10):S451.
54. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12): 1098-107.
55. Fox R, Phillips T, Kita M et al. Clinical efficacy of BG-12 in relapsingremitting multiple sclerosis (RRMS): data from the Phase 3 CONFIRM Study. Neurology. 2012;78(Meeting Abstracts 1):Abstract S01.003. Available at: http://www.neurology.org/cgi/content/meeting_abstract/78/1_ MeetingAbstracts/S01.003?sid=af365175-4af4-4001-bb50-b1b5c63eb7af. Accessed November 21, 2012.
56. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97.
57. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306(1-2):173-79.
58. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-09.
59. Vollmer T, Comi G, Sorensen PS, et al. Clinical efficacy of laquinimod for the treatment of multiple sclerosis: pooled analyses from the ALLEGRO and BRAVO phase III trials. Neurology. 2012;79:Abstract S01.007.
60. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis: a focus on alemtuzumab. Clin Immunol. 2012;142(1):25-30.
61. Coles A, Brinar V, Arnold D, et al. Efficacy and safety results from comparison of alemtuzumab and Rebif efficacy in multiple sclerosis I (CARE-MS I): a phase 3 study in relapsing-remitting treatment-naïve patients. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Neurology. 2012;78:Abstract S01.006
62. Cohen AJ, Twyman C, Arnold D et al. Efficacy and safety results from comparison of alemtuzumab and Rebif efficacy in multiple sclerosis II (CARE-MS II): a phase 3 study in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy. American Academy of Neurology (AAN) 2011 Annual Meeting. Neurology. 2012;78:Abstract S01.004.
63. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-94.
64. No authors listed. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-504.
65. No authors listed. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-85.
66. No authors listed. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61.
67. Kieseier BC, Stuve O. A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nat Rev Neurol. 2011;7(5):255-62.
68. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-14.
69. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97.
70. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to diseasemodifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
71. Elan Medical Information Services. TYS76 Tysabri PML Case Overview. October 19, 2012. Available at: https://www.google.com/url?sa=t&rct=j&q =&esrc=s&source=web&cd=1&cad=rja&ved=0CDEQFjAA&url=https%3 A%2F%2Fmedinfo.elan.com%2Fpdfs%2F220.pdf&ei=rumsUImPK4TY8gT yioHoCg&usg=AFQjCNHuzCeDRw00rcTQeGSBgnMdJHS9MA. Accessed November 20, 2012.
72. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-80.
73. Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012;78(6):436-37.
74. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology. 2002;59(6):909-13.
75. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler. 2009;15(4):505-08.
76. U.S. Food and Drug Administration. FDA drug safety communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). May 14, 2012. Available at: http://www. fda.gov/Drugs/DrugSafety/ucm303192.htm. Accessed November 18, 2012.
77. Fukushima R, Kanamori S, Hirashiba M, et al. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Toxicol Sci. 2009;108(2):419-26.
78. Fukushima R, Kanamori S, Hirashiba M, et al. Teratogenicity study of the dihydroorotatedehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol. 2007;24(3-4):310-16.
79. Stuve O, Benamor M, Bezerdjeb H, Kieseier B. Pregnancy outcomes from the teriflunomide clinical development program: retrospective analysis of a global pharmacovigilance database. Neurology. 2012;78:Abstract P06.190.
80. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm. 2012;18(1):54-62.
81. Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-78.
82. Kieseier BC, Wiendl H, Hartung HP, Leussink VI, Stuve O. Risks and benefits of multiple sclerosis therapies: need for continual assessment? Curr Opin Neurol. 2011;24(3):238-43.
83. World Health Organization. Adherence to long-term therapies: evidence for action. January 1, 2003. Available at: http://www.who.int/chp/knowledge/ publications/adherence_report/en/. Accessed November 18, 2012.
84. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51-61.
85. Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601-09.
86. Arroyo E, Grau C, Ramo C, Parra J, Sanchez-Solino O. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results]. Neurologia. 2010;25(7):435-42. [Article in Spanish]
87. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.
88. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255:(Suppl 6):S87-S92.
89. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568-76.
90. Markowitz C, Coyle PK, Zwibel H, Cohen B, Oleen-Burkey MK. Therapy characteristics at enrolment in the TOP MS study. Mult Scler. 2011;17(10 Suppl):S53-S276 P215.
91. Rinon A, Buch M, Holley D, Verdun E. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629-43.
92. Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K. Diseasemodifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol. 2011;11:122.
93. Turner AP, Kivlahan DR, Sloan AP, Haselkorn JK. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler. 2007;13(9):1146-52.
94. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-09.
95. Lipsy RJ. Will the newer oral MS agents be welcomed by managed care organizations? Am J Manag Care. 2010;16(8 Suppl):S227-S233.
96. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1-9.
97. Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012;12:7.
98. Anderson G, Meyer D, Herrman CE, et al. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. J Neurol. 2010;257(11):1917-23.
99. Stockl KM, Shin JS, Gong S, et al. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care. 2010;16(2):139-44.
100. U.S. National Institute of Health. Therapy optimization in multiple sclerosis (MS) (TOP MS). Clinicaltrials.gov. August 14, 2012. Available at: http:// clinicaltrials.gov/ct2/show/NCT00819000. Accessed November 18, 2012.
101. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8(6):545-59.
102. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol. 2008;255(Suppl 1):44-50.
103. Fendrick AM, Chernew ME. Value-based insurance design: a "clinically sensitive, fiscally responsible" approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med. 2007;22(6):890-891.
104. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-40.
105. Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Med Care Res Rev. 2004;61(4):415-52.
106. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42(7):626-34.
107. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-58.
108. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100.
109. Shortell SM, Casalino LP, Fisher ES. How the center for Medicare and Medicaid innovation should test accountable care organizations. Health Aff (Millwood). 2010;29(7):1293-98.
110. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-60.
111. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9):2031-48.
112. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-83.
113. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069-78.